ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - MSN
5 hours ago • Google News
Alnylam Pharmaceuticals Inc (ALNY)
US$ 289-1.22%
Price Chart
Key Statistics
Market Cap
$ 52.67B
P/E Ratio
0.00
Revenue (TTM)
$ 2.46B
Volume
614.1K
52W High
$ 402.43
52W Low
$ 205.87
Dividend Yield
0.00%
Beta
0.22
Technicals
50-Day MA
316.9852
200-Day MA
272.7325
52 Week High
402.43
52 Week Low
205.87
About ALNY
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
Employees
2230
Headquarters
Cambridge, MA
CEO
Dr. Yvonne L. Greenstreet M.B.A., M.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg